Rethinking brain health
We are on a mission to change the way the world thinks about brain health.
Oxford Brain Diagnostics is committed to analysing the cellular structure of the brain in a way no one else can, to support drug development and aid clinicians around the world in their fight to defeat Alzheimer’s and other neurodegenerative diseases.
Our novel technology assesses brain health based on changes in the cellular structure.
Our pioneering approach, and novel measures unlock unique insights that enable us to predict, detect, quantify, track and differentiate neurodegenerative diseases.
This gives us the potential to revolutionise how people think about brain health and disease management.
Supporting more efficient drug development and personalised patient care.
Previously inaccessible insights unlocked by our proprietary technology will support more targeted, efficient drug development.
Our products
Pharma/Biotech
- Measures you can trust
- Get more from your MRI
- Run targeted, more efficient clinical trials
- Efficient use of technology across multiple conditions
Clinical
- Better patient care
- Improving certainty in diagnosis
- Differential diagnosis for Dementia
- Accurately tracking decline
- Proactive brain health
Latest news
OBD Guest Speaker Series - Professor Jennifer Whitwell
Professor Jennifer Whitwell shares her thoughts on Progressive Supranuclear Palsy (PSP), the role Neuroimaging can play when combining modalities to support more effective diagnosis of this complex condition.
OBD Guest Speaker series - Lynne Hughes
Lynne Hughes (Co-Chair and Neurology Consultant from the Davos Alzheimer’s Collaborative (DAC)) provided an update and shared her thoughts on the DAVOS-DAC initiative.
Japan - Research Collaboration with Niigata Hospital
We are delighted to annouce our hospital based research collaboration with Dr Nakajima (Niigata Hospital) and Dr Shigematsu (Miniami Kyoto Hospital).
OBD Guest Speaker series - Professor Philip Scheltens
Professor Scheltens provided valuable insights on the pathway to precision medicine in Alzheimer’s disease.
